Chemiesynth(Vapi (539230)

Score breakdown: P/E: 0/3 · ROCE: 0/2 · Growth: 0/2 · Dividend: 0/1

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

Let me look at Chemiesynth(Vapi as Graham would: a small specialty chemicals company with a market cap of just ₹12 crore and a share price of ₹30.98, sitting below book value of ₹37.63. That P/B of 0.82 initially catches my eye. But a stock is not cheap simply because it trades below book; the book must earn a return. Here the numbers warn me. ROE is -12.19%, and the latest quarter lost ₹1 crore on sales of ₹5 crore. Profit growth has declined 48.94%. Book value is being eroded, not compounded. Sales growth of 31.19% is a positive, but growth without profits is often a trap. ROCE is only 3.10%, barely enough to attract me as a disciplined investor. The Piotroski F-Score of 4/9 reinforces weak financial health. There is no dividend, so the investor must rely on asset backing or future earnings. As a value investor, I prefer a durable moat. In specialty chemicals, a niche product with pricing power can be a good business, but I do not see evidence of a moat in these figures. At below book value, this is more of an asset play than a great business. I would demand a wide margin of safety because the quality is poor. Mr. Market has marked the stock down from ₹60.63 to its 52-week low, and with negative earnings I can understand the pessimism. If the company can turn sales into profits, there may be a turnaround. If not, the discount to book may be fair. I will not buy based on hope. I need evidence of improving margins, stable returns on capital, and eventually earnings that justify the book value.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer